28 August 2025 in Terapevticheskii arkhiv
Aim. To study the ability and significance of detecting liver steatosis during chest computed tomography (CT) in patients with viral pneumonia. Materials and methods. A prospective cohort study included 100 patients over the age of 18 who were hospitalized with an established diagnosis of viral pneumonia. To CT detection significant liver steatosis (more than 33%), several approaches were used: liver density less than 40 HU; decrease in liver density by at least 10 HU less than the spleen; the ratio of decrease in liver density to the spleen is less than 0.9. Results. According to CT data 2 groups were identified: 25 patients with existing liver steatosis and metabolically associated fatty liver disease, and 74 patients of the control group without signs of significant steatosis, оne patient was excluded due to alcohol abuse. There was a significant difference in the study of liver density (31.68 ± 10.67 and 54.44 ± 5.95; p 0.001), the ratio of decrease in liver density to spleen density (0.66 ± 0.22 and 1.16 ± 0.13; p 0.001), as well as a decrease in liver density relative to the spleen (16.30 ± 10.38 and -7.26 ± 6.10; p 0.001). In the steatosis group, a more severe course of pneumonia was noted (p = 0.041). The incidence of deterioration according to CT was comparable in both groups: 19 (76%) and 45 (60.8%); p = 0.169, although its severity was higher in the group with steatosis (p = 0.012). Patients from the steatosis group were significantly more often prescribed biological (88.0 and 39.19%; p 0.001) and antibacterial therapy (68.0 and 40.54%; p = 0.017). Conclusion. The use of assessment of liver steatosis according to CT data simultaneously with the study of the underlying disease can become an important diagnostic step determining the prognosis of the course of the disease, as well as a tool for risk stratification in patients with metabolically associated fatty liver disease.
1 October 2025 in Translational Gastroenterology and Hepatology
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a common form of chronic liver disease, found in more than a quarter of the world’s population. People with MASLD are at a high risk of acquiring severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The risk of a mild cold turning into severe pneumonia is also high. The aim of our study was to evaluate the effect of MASLD as a risk factor for the severity of coronavirus disease-associated pneumonia (COVID-AP). Methods: Our prospective, Russian cohort study included 100 adults (≥18 years old), of any sex, with COVID-AP. The SARS-CoV-2 infection was confirmed on nucleic acid amplification or using the SARS-CoV-2 antigen tests. Any possible secondary causes of liver steatosis were excluded, and alcohol consumption was assessed. The presence of significant hepatic steatosis (more than 30%) was estimated from computed tomography (CT) results. Results: Based on the presence of significant steatosis, in combination with other metabolic factors, two groups were formed: 25 patients with MASLD and 74 patients without significant steatosis, serving as controls. One patient was excluded from the MASLD group due to alcohol abuse. The two groups were comparable by sex (P=0.58) and age (P=0.96). Body mass index (BMI) (P<0.001), waist circumference (P<0.001), and obesity rate (P=0.001) were significantly higher in the MASLD group. Presence of hypertension (HTN) (P=0.52) and type 2 diabetes mellitus (T2DM) (P=0.06) were comparable in the two groups. Based on the initial higher volume of lung damage upon admission (P=0.04), an increase in lung damage during standard glucocorticosteroid therapy and an anticoagulant drug (P=0.01), the higher levels level of C-reactive protein (P=0.01), and the need for biological therapy, pneumonia in the MASLD group was more severe compared with the control group. The relationship between the biological therapy and metabolic factors variables had an odds ratio (OR) of 11.4; P<0.001 for hepatic steatosis and of 2.3; P=0.046 for obesity. No association with T2DM (P=0.61) and HTN was found (P=0.76). To eliminate the possible interaction between obesity and hepatic steatosis, the Mantel-Hensel test was used. The adjusted OR for steatosis was 10.2; P=0.001 and for obesity the OR was 1.39; P=0.49. The need for antibiotic therapy was associated with the significant presence of steatosis (OR =3.1; P=0.02) and T2DM (OR =6.8; P=0.008), adjusted OR for steatosis was 2.6; P=0.057. The duration of hospitalisation between the two groups was comparable (P=0.07). Mortality was significantly increased in the MASLD group (P=0.02). Conclusions: Liver steatosis, regardless of other metabolic risk factors, increased the need for biological therapy, whereas the need for antibiotic therapy was a consequence of T2DM. Our study showed a more severe course of COVID-AP in people with MASLD and higher mortality.